Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

1.0K
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
1.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dyskeratosis Congenita with Pigmentary Mosaicism and Hematopoietic Trisomy 9 in a Female Associated with a de novo DKC1 Variant and Markedly Skewed X Chromosome Inactivation.

NPJ genomic medicine·2026
Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026
Same author

Myeloperoxidase promotes fibrosis by inhibiting cathepsin K to bias the lung toward ECM accumulation.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: Tissue-resident macrophage survival depends on mitochondrial function regulated by SerpinB2 in chronic inflammation.

Nature communications·2026
Same author

Regulatory Effects of CD14<sup>+</sup>CD16<sup>++</sup>Slan<sup>+</sup> Monocytes on Classical Monocytes and T Lymphocytes in Response to Inflammatory and Phagocytic Stimuli.

Journal of immunology research·2026
Same author

SenSet defines cell-type specific senescence signatures in the aged human lung.

The EMBO journal·2026

Related Experiment Video

Updated: May 5, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K

Protease activated receptor-2 contributes to heart failure.

Silvio Antoniak1, Erica M Sparkenbaugh, Michael Tencati

  • 1UNC McAllister Heart Institute, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Plos One
|December 7, 2013
PubMed
Summary

Protease-activated receptor-2 (PAR-2) signaling drives heart hypertrophy and failure. Inhibiting PAR-2 may offer a therapeutic strategy for preventing cardiac remodeling and improving function after heart attacks.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

10.8K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K

Related Experiment Videos

Last Updated: May 5, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.3K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

10.8K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • G protein-coupled receptor signaling

Background:

  • Heart failure is a significant global health issue.
  • G protein-coupled receptors, particularly protease-activated receptors (PARs), are implicated in cardiac hypertrophy and failure.
  • PAR-2 activation on cardiomyocytes promotes hypertrophic growth and contributes to adverse cardiac remodeling post-myocardial infarction.

Purpose of the Study:

  • To investigate the role of PAR-2 in cardiomyocyte hypertrophy, fibrosis, and heart failure.
  • To elucidate the signaling pathways involved in PAR-2-mediated cardiac effects.
  • To evaluate the therapeutic potential of targeting PAR-2 in myocardial infarction.

Main Methods:

  • Utilized cultured rat and mouse neonatal cardiomyocytes to assess PAR-2 effects on hypertrophy and gene expression.
  • Employed cardiomyocyte-specific PAR-2 overexpression in mice to model cardiac pathology.
  • Generated a mouse model of myocardial infarction using permanent coronary artery ligation and assessed the impact of PAR-2 deficiency.

Main Results:

  • PAR-2 activation induced hypertrophic growth in cardiomyocytes via MEK1/2 and p38 signaling.
  • PAR-2 increased expression of the pro-fibrotic chemokine MCP-1 in cardiomyocytes.
  • Cardiomyocyte-specific PAR-2 overexpression led to heart hypertrophy, fibrosis, inflammation, and heart failure in mice.
  • PAR-2 deficiency attenuated cardiac remodeling and improved function following myocardial infarction, independent of infarct size.

Conclusions:

  • PAR-2 signaling is a key driver of cardiac hypertrophy and heart failure.
  • Targeting PAR-2 represents a potential therapeutic strategy for managing heart disease and improving outcomes after myocardial infarction.